Enzolytics Inc (ENZC)

[falon]

Regeneron Pharmaceuticals, Inc. discretely revealed its intentions to expand its Anti-SARS-CoV-2 Monoclonal Antibody offerings at the J.P. Morgan Healthcare Conference on January 9, 2023.

Regeneron's presentation stated that in the U.S. alone, millions of immuno-compromised people will not adequately respond to vaccination.

And antibodies can be dosed prophylactically to prevent infection and severe COVID-19 disease.

On slide #27, the Company stated its 'Next-gen COVID antibody binds outside variable RBD and has demonstrated high neutralization activity against all known variants and lineages and disclosed it anticipates initiating the REGN14287 phase 3 clinical trial in 2023, pending regulatory discussions.

The NCT04425629 study was last updated on July 29, 2022.

https://www.precisionvaccinations.com/2023/01/11/regenerons-next-gen-monoclonal-antibody-revealed